Abstract
The presence of hypertension among the population with human immunodeficiency virus (HIV) has become a new threat to the health and well-being of people living with this disease, in particular, among those who received antiretroviral therapy. The estimated prevalence of high blood pressure in HIV‐infected patients is significantly higher than the rate observed in HIV‐uninfected subjects. The approach to the HIV-positive patient requires the assessment of individual cardiovascular risk and its consideration when designing the individualized target. On the other hand, the numerous pharmacological interactions of antiretroviral (ARV) drugs are essential elements to take into account. Serum levels of any kind of antihypertensive drugs may be influenced by the coadministration of protease inhibitors, non-nucleoside reverse transcriptase inhibitor, or other antiretroviral. Similarly, plasma concentrations of antiretroviral drugs can be increased by the concomitant use of calcium channel blockers or diuretics. In this regard, the treatment of high blood pressure in HIV patients should be preferentially based on ACE inhibitors or thiazide/thiazide-like diuretics or their combination.
Keywords: Antiretroviral, hypertension, antihypertensive treatment, HIV infection, interactions, cardiovascular disease.
Current Pharmaceutical Design
Title:Antiretroviral Treatment and Antihypertensive Therapy
Volume: 27 Issue: 40
Author(s): Nicolás R. Robles*, Francesco Fici, Julian Valladares and Guido Grassi
Affiliation:
- Servicio de Nefrologia, Hospital Universitario de Badajoz, Badajoz,Spain
Keywords: Antiretroviral, hypertension, antihypertensive treatment, HIV infection, interactions, cardiovascular disease.
Abstract: The presence of hypertension among the population with human immunodeficiency virus (HIV) has become a new threat to the health and well-being of people living with this disease, in particular, among those who received antiretroviral therapy. The estimated prevalence of high blood pressure in HIV‐infected patients is significantly higher than the rate observed in HIV‐uninfected subjects. The approach to the HIV-positive patient requires the assessment of individual cardiovascular risk and its consideration when designing the individualized target. On the other hand, the numerous pharmacological interactions of antiretroviral (ARV) drugs are essential elements to take into account. Serum levels of any kind of antihypertensive drugs may be influenced by the coadministration of protease inhibitors, non-nucleoside reverse transcriptase inhibitor, or other antiretroviral. Similarly, plasma concentrations of antiretroviral drugs can be increased by the concomitant use of calcium channel blockers or diuretics. In this regard, the treatment of high blood pressure in HIV patients should be preferentially based on ACE inhibitors or thiazide/thiazide-like diuretics or their combination.
Export Options
About this article
Cite this article as:
Robles R. Nicolás*, Fici Francesco , Valladares Julian and Grassi Guido, Antiretroviral Treatment and Antihypertensive Therapy, Current Pharmaceutical Design 2021; 27 (40) . https://dx.doi.org/10.2174/1381612827666210810090805
DOI https://dx.doi.org/10.2174/1381612827666210810090805 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of Nitric Oxide Pathway by Multiligands/RAGE Axis: A Crossing Point on the Road to Microvascular Complication in Diabetes
Current Enzyme Inhibition Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets Nitric Oxide Synthase and Cyclooxygenase Pathways: A Complex Interplay in Cellular Signaling
Current Medicinal Chemistry Effect of Antioxidant Extract from Cherries on Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Antenatal Glucocorticoids Supplementation and Central Nervous System Development
Current Drug Metabolism Living Heart Valve and Small-Diameter Artery Substitutes - An Emerging Field for Intellectual Property Development
Recent Patents on Biotechnology MicroRNAs in Arterial Hypertension
Current Topics in Medicinal Chemistry Seeking Novel Targets for Improving In Vivo Macrophage-Specific Reverse Cholesterol Transport: Translating Basic Science into New Therapies for the Prevention and Treatment of Atherosclerosis
Current Vascular Pharmacology Piperine: Medicinal, Analytical and Therapeutics perspective
Current Bioactive Compounds Recent Advances in Fe-MOF Compositions for Biomedical Applications
Current Medicinal Chemistry Treating Dyslipidemias: Is Inflammation the Missing Link?
Medicinal Chemistry Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives
Current Pharmaceutical Design Natural Agents Modulating ACE-2: A Review of Compounds with Potential against SARS-CoV-2 Infections
Current Pharmaceutical Design Protease-Activated Receptor 2: Are Common Functions in Glial and Immune Cells Linked to Inflammation-Related CNS Disorders?
Current Drug Targets The Epidemiology and Health Effects of Tobacco Smoke Exposure
Current Pediatric Reviews Adipose Tissue: Something More than Just Adipocytes
Current Nutrition & Food Science Memantine Treatment in Patients with Mild to Moderate Alzheimers Disease Already Receiving a Cholinesterase Inhibitor: A Randomized, Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Tyrosine Kinases and Inflammatory Signalling
Current Molecular Medicine Ethosomes as Vesicles for Effective Transdermal Delivery: From Bench to Clinical Implementation
Current Clinical Pharmacology Microcirculatory Dysfunction in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets